0000899243-19-014037.txt : 20190517 0000899243-19-014037.hdr.sgml : 20190517 20190517182722 ACCESSION NUMBER: 0000899243-19-014037 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190516 FILED AS OF DATE: 20190517 DATE AS OF CHANGE: 20190517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolchko J Scott CENTRAL INDEX KEY: 0001586893 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 19837175 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-16 0 0001434316 FATE THERAPEUTICS INC FATE 0001586893 Wolchko J Scott C/O FATE THERAPEUTICS, INC.; 3535 GENERAL ATOMICS COURT #200 SAN DIEGO CA 92121 1 1 0 0 President and CEO Common Stock 2019-05-16 4 M 0 14335 1.63 A 389216 D Common Stock 2019-05-16 4 S 0 2298 18.464 D 386918 D Common Stock 2019-05-16 4 S 0 12037 19.5442 D 374881 D Stock Option (right to buy) 1.63 2019-05-16 4 M 0 14335 D 2022-02-08 Common Stock 14335 0 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Represents the weighted average sale price of the shares sold ranging from $18.24 to $19.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Represents the weighted average sale price of the shares sold ranging from $19.24 to $19.91 per share. The Reporting person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. The shares subject to this option became fully vested and exercisable on October 4, 2015. Not applicable. /s/ Cindy R. Tahl, as Attorney-in-Fact 2019-05-17